MedTrace Logo

Exhaled Nitric Oxide and Nasal Lavage Fluid

NCT00773578 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2009-02-13

No results posted yet for this study

Summary

The allergic respiratory diseases such as asthma or allergic rhinitis are the main chronic diseases in children. The airway inflammation plays an important role in their pathophysiology. Several epidemiological studies show that environmental tobacco smoke (ETS) exacerbates the symptoms of asthma and allergies.

The aim of this study is to assess the impact of environmental tobacco smoke on the measurement of exhaled nitric oxide (eNO) and biomarkers of nasal inflammation in atopic asthmatic children.

Conditions

Interventions

DEVICE

Measurement of exhaled nitric oxide (eNO)

Chemiluminescence NO analyzer Measurement of lung function (spirometry)

DEVICE

Measurement of biomarkers of nasal inflammation

Nasal lavage

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jocelyne JUST, MdPh · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
5 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-09-30
Completion
2009-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00773578 on ClinicalTrials.gov